Skip to main content
Heptares to advance gastrointestinal disease study with Imperial College London
1/12/2018

Heptares Therapeutics and Imperial College London agreed on a multiyear research and development deal focused on gastrointestinal disease. Under the collaboration, Heptares will fund and support the studies of work up to commercialization of any product resulting from the deal.

Full Story: